Clinical Trial Update: A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/2 dose-exploration study to evaluate the safety and efficacy of BEAM-301 in patients with Glycogen Storage Diseas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glycogen Storage Disease Type Ia

Drugs mentioned

• BEAM-301

Snippet

Sponsor: Beam Therapeutics Inc. | Conditions: Glycogen Storage Disease Type Ia | Phase 1, Phase 2 | Status: RECRUITING